Original ContributionPrevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer
References (32)
Menopause and breast cancer: symptoms, late effects, and their management
Semin Oncol
(2001)- et al.
Gonadotropin-releasing hormone receptor antagonists
Lancet
(2001) - et al.
Postmenopausal vaginal atrophy and atrophic vaginitis
Am J Med Sci
(1997) - et al.
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study
Lancet
(1998) - et al.
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
Lancet
(1998) Comparative study: Replens versus local estrogen in menopausal women
Fertil Steril
(1994)A randomized, open, parallel-group study on the preventive effect of estradiol-releasing vaginal ring on recurrent urinary tract infections in postmenopausal women
Am J Obstet Gynecol
(1999)Hormone receptors in breast cancer: racial differences in distribution and survival
Breast Cancer Res Treat
(2002)Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial
Lancet
(2002)- et al.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer
N Engl J Med
(2003)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
N Engl J Med
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
N Engl J Med
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group
J Clin Oncol
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimedex Study Group
J Clin Oncol
Aromatase Inhibitors in Breast Cancer
N Engl J Med
Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer
J Clin Oncol
Cited by (63)
Photobiomodulation and vulvovaginal disorders after anticancer treatments
2023, Bulletin du CancerThe Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
2019, Clinical Breast CancerCitation Excerpt :The first line of non-hormone therapy includes widely available paraben-free vaginal moisturizers and lubricants (water, mineral or plant oil, or silicone-based), especially in women with mild to moderate symptoms of genitourinary syndrome of menopause.13 Vaginal estrogen therapy can restore normal, complex physiological functions of estrogens in the female lower urogenital tract14-17 and is reserved for the treatment of the patients with severe symptoms of VVA.18 However, this therapeutic modality use in patients with estrogen receptor-positive (ER+) breast cancer continues to be debated because of concerns regarding long-term safety.
The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis
2019, Clinical Breast CancerCitation Excerpt :GSM affects 20% to 50% of women after menopause.4-6 In patients with BC, who undergo menopause at an accelerated rate (eg, drug-induced such as with chemotherapy, or use of chemical ovarian suppression with GnRH agonists) or undergo a more severe degree of hypo-estrogenic state owing to use of aromatase inhibitor therapy, symptoms of GSM can occur sooner and be more severe than those found among women with a normal-paced menopause.7-9 Symptoms are often not disclosed by patients because of embarrassment.
Cancer therapy–related vaginal toxicity: its prevalence and assessment methods—a systematic review
2024, Journal of Cancer Survivorship
This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.
Electronic forwarding or copying is a violation of US and international copyright laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.